Immunovaccine Ltd.

ImmunoVaccine Technologies Inc. (IVT) is a clinical stage private biotechnology company developing therapeutic cancer and prophylactic infectious disease vaccines for human health. IVT is commercializing breakthrough vaccines developed through the combination of the VacciMax® platform, a vaccine delivery and enhancement system and a large selection of validated vaccine antigens. The combination of the right antigens and strong novel delivery will give IVT’s pipeline a distinct competitive advantage and will position IVT as a key player in development of premium vaccine products.